secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001453687-25-000084
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics Q1 net loss $17.7M; cash $182.1M; Phase 3 AURORA on track
--------------------------------------------------------------------------------

- Net loss of $17.7M ($0.68 basic loss per share) vs $56.8M ($10.50) in Q1 2024; R&D expenses rose to $14.7M.
- Cash, equivalents and restricted cash $182.1M as of March 31, 2025; expected to fund operations into mid-2027.
- Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) expected to begin in Q2 2025 with ~100 participants.
- Phase 2b data showed sustained MG-ADL reduction of 4.8 points at Month 12; deeper 7.1-point drop in biologic-naïve subgroup.
- Preliminary Phase 2 SLE data and Phase 2 pediatric basket trial initiation expected in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000084/0001453687-25-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000084/rnac-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001453687-25-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer